Validation of the Edmonton Symptom Assessment System: Ascites Modification

Masanori Mori, Tatsuya Morita, Naosuke Yokomichi, Akihiro Nitto, Naoko Takahashi, Shingo Miyamoto, Hiroyuki Nishie, Junji Matsuoka, Hiroki Sakurai, Tatsuhiko Ishihara, Yoko Tarumi, Asao Ogawa

Research output: Contribution to journalArticle

Abstract

Context: Few patient-reported outcomes are available to measure the symptoms associated with malignant-related ascites in patient care and clinical research. Although the Edmonton Symptom Assessment System: Ascites Modification (ESAS:AM) is a brief tool to measure symptoms associated with malignant-related ascites, it remains to be fully validated. Objectives: The objective of the study was to validate the ESAS:AM in Japanese cancer patients. Methods: We assessed the internal consistency, test-retest reliability, concurrent validity, and construct validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS:AM, M.D. Anderson Symptom Inventory, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30, and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module. Results: Cronbach's alpha coefficient of the ESAS:AM was 0.89. The intraclass correlation coefficient on test-retest examination of its total score was 0.93 (P < 0.001). Pearson correlation coefficients of the total score of the ESAS:AM with the total score of the M.D. Anderson Symptom Inventory and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module ranged from 0.44 to 0.81 (P < 0.001) and those with global health status/quality of life and functional subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 ranged from −0.40 to −0.61 (P < 0.001). The total scores of the ESAS:AM were significantly higher in 20 patients with symptomatic ascites (34 [SD, 26]) than 267 patients without symptomatic ascites (23 [SD, 19]) (P = 0.018). Conclusion: The ESAS:AM is a reliable and valid tool for measuring symptoms associated with malignant-related ascites and can be used in daily patient care and future epidemiological studies and clinical trials.

Original languageEnglish
Pages (from-to)1557-1563
Number of pages7
JournalJournal of Pain and Symptom Management
Volume55
Issue number6
DOIs
Publication statusPublished - Jun 2018

Keywords

  • Edmonton Symptom Assessment System: Ascites Modification
  • cancer
  • malignant-related ascites
  • reliability
  • validation
  • validity

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Validation of the Edmonton Symptom Assessment System: Ascites Modification'. Together they form a unique fingerprint.

  • Cite this

    Mori, M., Morita, T., Yokomichi, N., Nitto, A., Takahashi, N., Miyamoto, S., Nishie, H., Matsuoka, J., Sakurai, H., Ishihara, T., Tarumi, Y., & Ogawa, A. (2018). Validation of the Edmonton Symptom Assessment System: Ascites Modification. Journal of Pain and Symptom Management, 55(6), 1557-1563. https://doi.org/10.1016/j.jpainsymman.2018.03.016